Company intelligence / Profile preview

Y-mAbs Therapeutics, Inc.

New York, New York, United Statesorpha.net ↗

Ownership: Public · YMAB
Development stage: Commercial

Overview

Y-mAbs has FDA-approved treatment DANYELZA (naxitamab-gqgk) for patients with relapsed or refractory high-risk neuroblastoma. The company is conducting Phase I/II and Phase II clinical trials for various indications.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodies (BsAbs)VaccinesRadioimmunotherapiesDiagnostics
Industry: Biotech

Drug pipeline

23 assets

naxitamab

Approved

22 more assets in the full pipeline.

Request access →

Partnerships

Memorial Sloan Kettering Cancer Center (MSKCC)

Financials

Market cap: $391.2M
Total revenue: $19.5M
Enterprise value: $334.7M

Beyond the preview

Go deeper on Y-mAbs Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y-mAbs Therapeutics, Inc..

Explore the full profile